Not only is it the first Alzheimer’s antibody treatment to get full FDA approval, it’s also the first that will be broadly covered by Medicare.
The Food and Drug Administration approved the early Alzheimer’s treatment Lequembi on Thursday—a critical step in making the expensive drug more accessible to American seniors. Leqembi is notoriously expensive, with a more than $26,000 yearly cost, making its Medicare coverage crucial.
Alzheimer’s is the sixth leading cause of death in the United States, according to the FDA, and Leqembi has been shown to modestly slow cognitive decline from the disease. During the drugmaker’s clinical trial, Leqembi slowed cognitive decline in early Alzheimer’s patients by 27% over 18 months. It also carries some serious risks, including swelling and bleeding of the brain. Three participants in the clinical trial died, but FDA scientists said it’s unclear whether Leqembi was to blame.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Baca lebih lajut »
FDA Approves First Leadless Dual-Chamber Pacing SystemThe FDA has approved 'the world's first' leadless dual-chamber pacing system, one based in part on an already-approved leadless single-chamber device. MedicalNews CardioTwitter
Baca lebih lajut »
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More PatientsThe FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
Baca lebih lajut »
New Bill Would Require Medicare to Cover 'Home Resiliency' Amid Worsening Climate Crisis“Climate justice is a matter of disability justice,' said Sen. Ed Markey. 'It's time that we guarantee that seniors and people with disabilities can safely weather the climate crisis.'
Baca lebih lajut »
Op-ed: Medicare agency limiting access to Alzheimer’s treatmentCommentary: A new treatment for Alzheimer’s disease, lecanemab, will likely receive traditional FDA approval on Thursday. Unfortunately, the Centers for Medicare & Medicaid Services is closing the door to ready access to this new treatment.
Baca lebih lajut »